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Abstract: Among the major issues in gene expression proﬁ  le classiﬁ  cation, feature selection is an important and necessary 
step in achieving and creating good classiﬁ  cation rules given the high dimensionality of microarray data. Although different 
feature selection methods have been reported, there has been no method speciﬁ  cally proposed for paired microarray ex-
periments. In this paper, we introduce a simple procedure based on a modiﬁ  ed t-statistic for feature selection to microarray 
experiments using the popular matched case-control design and apply to our recent study on tumor metastasis in a low-
malignant group of breast cancer patients for selecting genes that best predict metastases. Gene or feature selection is op-
timized by thresholding in a leaving one-pair out cross-validation. Model comparison through empirical application has 
shown that our method manifests improved efﬁ  ciency with high sensitivity and speciﬁ  city.
Keywords: gene expression microarray, feature selection, metastasis, prediction.
Introduction
Characterized by simultaneous proﬁ  ling for the transcriptional activities of thousands of mRNA species 
in a human tissue, the DNA microarray technology represents an important high-throughput platform 
for analyzing and understanding human diseases. The tremendous potential provided by the new tech-
nology is serving us not only as a molecular tool for investigating disease mechanisms but also for 
classiﬁ  cation and clinical outcome prediction (Dudda-Subramanya et al. 2003). Application of the 
technology in clinical oncology is demonstrating it as a powerful tool for reﬁ  ning diagnosis and improving 
prognostic prediction accuracy of cancer patients (Pusztai et al. 2003). Bioinformatics and biostatistics 
play important roles in such practices in establishing gene expression signatures or prognostic markers 
and in building up efﬁ  cient classiﬁ  ers (Asyali et al. 2006). Among the major issues in gene expression 
proﬁ  le classiﬁ  cation, feature selection is an important and necessary step in achieving and creating good 
classiﬁ  cation rules given the high dimensionality of microarray data. There are various approaches for 
feature selection in the literature among which one common approach is the univariate selection scheme 
for selecting only genes with the highest statistical signiﬁ  cance. Such an approach can be inadequate 
because (1) it tends to include elements that contribute highly redundant information and (2) it ignores 
the co-regulatory network in gene function. As a result, the univariate approach does not necessarily 
guarantee a best classiﬁ  er (Ein-Dor et al. 2005; Baker and Kramer, 2006).
Tibshirani et al. (2002) proposed a Nearest Shrunken Centroids (NSC) method for both feature selec-
tion and tumor classiﬁ  cation. In NSC, weak elements of the class centroids are shrunk or deleted via 
soft-thresholding to identify genes that best characterize each class. The method implemented in an R 
package (PAM, Prediction Analysis of Microarrays) performs well in identifying subsets of genes that 
can be used for classiﬁ  cation and prediction. Although different feature selection methods have been 
reported for tumor classiﬁ  cation (Inza et al. 2004), there has been no method speciﬁ  cally proposed for 
paired microarray experiments. In this paper, we introduce a simple feature selection procedure based 
on a modiﬁ  ed t-statistic to microarray experiments using the popular matched case-control design and 
apply to our recent study on tumor metastasis in a low-malignant group of breast cancer patients for 
selecting genes that best predict metastases. Gene or feature selection is optimized by thresholding in a 
leaving one-pair out cross-validation procedure using the support vector machines (SVM) (Brown 
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et al. 2000). Such an approach is necessary consid-
ering the advantages in a matched design because 
there are multiple factors (nodal status, tumor size, 
age, etc.) that convey important implications on 
tumor outcomes. Performance of the feature selec-
tion method is compared with that from PAM and 
from the ordinary paired t-test using receiver oper-
ating characteristics (ROC) analysis (Fawcett, 
2006). 
Methods
Suppose in a paired microarray experiment, we 
have the gene expression values (usually in log 
scale) from n pairs of samples j = 1, 2, … n. For 
each gene i (i = 1, 2, … p), we obtain the differential 
gene expression in pair j, dij, by substracting the 
expression value of the control from the case and 
calculate the mean difference as dd n ij
n
ij = = Σ 1 / and 
the standard error of di as sd d n ij
n
ij i =− − = Σ 1
2 1 () / ( )  
Now we can calculate the t-test statistic for the 
paired data as
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Similar to Tusher et al. (2001), we add a positive 
constant s0 to the denominator of (1) so that (1) 
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From (2) we can see that our modiﬁ  ed t-statistic is 
a down-scaled t-statistic with the scaling deter-
mined by the ratio between s0 and si. Once s0 is 
speciﬁ  ed, the scaling has a large effect on genes 
with small standard errors. Following Tibshirani et al. 
(2002), we set s0 to the median value of si (i = 1, 
2, … p). For the purpose of feature selection, we 
specify a threshold Δ and pick up genes with 
|| ′ −> ti Δ 0. The optimal subset of genes is obtained 
through a leaving one-pair out cross-validation 
procedure using SVM. Similar to PAM, the optimal 
threshold Δ is determine through a grid search in 
which for each given Δ, the performance of classiﬁ  er 
is judged by leaving one-pair out cross-validation 
to ensure that the training set and the prediction set 
are independent. The Δ that corresponds to the 
lowest classiﬁ  cation error is taken as the optimal 
threshold. Once the optimal threshold Δ is deter-
mined, the overall optimal sub-set of genes is 
selected by applying the optimal Δ to the whole 
sample. The realization of SVM is done using the 
svm procedure in the R package e1071 (http://cran.
at.r-project.org/src/contrib/PACKAGES).
In order to assess and compare our model 
performance with that from PAM and the ordinary 
paired t-test, we introduce the ROC analysis and 
calculate the area under an ROC curve (AUC). A 
ROC curve is a two-dimensional depiction of clas-
siﬁ  er performance which plots sensitivity on the Y 
and 1-speciﬁ  city on the X axes. As such, a high-
AUC classiﬁ  er has better average performance than 
a low-AUC classifier (Fawcett, 2006) with 
AUC = 0.5 for a random classiﬁ  er. ROC analysis 
is performed using the free R package caTools.
Application
We apply our method to a microarray dataset on 
tumor metastasis from low-malignant breast cancer 
patients collected in our lab (Thomassen et al. 
2006a). In this study, 13 low-malignant T1 (tumor 
size in diameter T ≤ 20 mm) and 17 low-malignant 
T2 (20 mm < T ≤ 50 mm) tumors from patients 
who developed metastases were matched to metas-
tasis-free tumors from patients (followed up for 
about 12 years after diagnosis) of the same tumor 
type and according to year of surgery, tumor size, 
and age. Gene expression analysis was performed 
on 29K oligonucleotide arrays with duplicated 
measurements for each gene (Thomassen et al. 
2006b). Data were normalized using the variance 
stabilization normalization method (Huber et al. 
2002) implemented in the free R package vsn in 
Bioconductor (http://www.bioconductor.org). The 
study by Thomassen et al. (2006a) identiﬁ  ed a 32-gene 
signature that classiﬁ  es the 60 tumor samples with 
a mean accuracy of 78% (speciﬁ  city 77%; sensi-
tivity 80%) using leaving one-pair out cross-valida-
tion (Figure 1a). In the analysis, feature selection 
was done using the nearest shrunken centroids 
methods in the R package pamr (Tibshirani et al. 
2002) and classiﬁ  cation done using SVM in the R 
package e1071. Note that the feature selection 
procedure using pamr does not take the paired 
matching into account in identifying the subset of 
genes for training and prediction. 
Using our method described above, we re-analyze 
the data by introducing the modiﬁ  ed t-statistic for Cancer Informatics 2007:3 215
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Figure 1. Probability of metastasis calculated by SVM using leaving 
one-pair out cross-validation based on the 32-gene signature by PAM 
(1a), the 5-gene signature by our new method (1b) and the 43-gene 
signature by paired t-test (1c) for the 13 pairs of low-malignant T1 
(asterisk) and 17 pairs of low-malignant T2 (triangle) patients. The 
best performance is achieved by our 5-gene signature with improved 
prediction accuracy and better separation. 
paired data in deﬁ  ning the gene expression signature 
for predicting metastases. Our analysis achieved an 
overall accuracy of 83% (∆ = 0.396) with a speciﬁ  city 
of 83% and a sensitivity of 83% using a subset of 
only 5 genes (Figure 1b). Comparing Figure 1a with 
1b, one can see that our method has improved sepa-
ration based on prediction probability and increased 
efﬁ  ciency (median of correct prediction proba-
bility: 0.88 versus 0.86 for metastasis and 0.84 
versus 0.81 for non-metastasis). Interestingly, all 
the 5 selected genes are within the 32-gene list 
identiﬁ  ed by PAM in Thomassen et al. (2006a). To 
further compare our analysis, we additionally 
introduce the ordinary paired t-test for gene selec-
tion. Here the thresholding is imposed upon the 
ordinary paired t-statistic, i.e. we pick up genes with 
|| ti −> Δ 0. Likewise, we again select the optimal 
subset of genes through cross-validation by leaving 
one-pair out. The classiﬁ  er based on the expression 
signature speciﬁ  ed by the ordinary paired t-test yields 
an average accuracy of 74% (speciﬁ  city 74%; 
sensitivity 74%) when ∆ is set to 3.1 (43 genes 
selected). The cross-validation probabilities plotted 
in Figure 1c shows that the model based on ordi-
nary paired t-test has the lowest efﬁ  ciency (median 
of correct prediction probability: 0.85 for metas-
tasis and 0.83 for non-metastasis) even though the 
method makes use of the paired design. 
We ﬁ  nally evaluate the overall performances of 
the 3 methods using ROC analysis. Based on the 
cross-validation probability of metastasis from SVM 
and the observed metastasis status for each sample, 
we are able to draw the ROC curves and show it in 
Figure 2 with the dotted curves for the new method 
in black, for PAM in red and for the paired t-test in 
green. Visualization of Figure 2 indicates that since 
the black curve runs on top of the other curves in 
the upper-left triangle of the ﬁ  gure, our new method 
exhibits higher efﬁ  ciency as compared with the 
others. This is further conﬁ  rmed by calculating the 
AUC, a standard summary metric for assessing the 
overall performance of a classiﬁ  er. The high AUC 
for our new method (0.86) again shows that it 
outperforms PAM (AUC = 0.83) and the ordinary 
paired t-test (AUC = 0.80). 
Discussion
We have introduced a simple feature selection 
method for predicting tumor metastases in paired 
microarray experiments. Model comparison 
through empirical application has shown that our Cancer Informatics 2007:3 216
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method manifests high efﬁ  ciency and outperforms 
existing methods. As shown in the results section, 
the ordinary paired t-tests has the worst perfor-
mance as compared with the other two methods 
which use modiﬁ  ed t-statistics for thresholding to 
eliminate genes that do not contribute towards 
class prediction. Although both the modiﬁ  ed and 
the ordinary paired t-statistics make use of the 
matched design, the better performance of our 
method is achieved by thresholding upon a new 
metric that is less dependent on gene-speciﬁ  c vari-
ances which helped to ﬁ  lter statistically signiﬁ  cant 
genes due to small standard errors in their differ-
ential expressions. It is more interesting to 
compare the performances between our method 
and PAM. Although both methods use the modiﬁ  ed 
versions of t-statistics, our method takes the 
following advantages of the paired design in 
selecting informative features. First, as a popular 
method in cancer research (Breslow and Day, 
1990), the paired design helps to minimize the 
inﬂ  uence on tumor metastasis from non-transcrip-
tomic factors such as age, clinical stage, treatment, 
etc (Gonzalez-Angulo et al. 2005). Second, in a 
transcriptomic study on tumor metastasis, these 
confounding factors not only affect the metastasis 
phenotype which is of our primary interest but 
could also inﬂ  uence the transcriptional proﬁ  les of 
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Figure 2. ROC analysis for model comparison with the dotted curves for the new method in black, for PAM in red and for the paired t-test in 
green. Since the black curve runs on top of the others in the upper-left triangle of the ﬁ  gure, our new method exhibits higher efﬁ  ciency in its 
performance. The high AUC for our new method (0.86) indicates that it outperforms PAM (AUC = 0.83) and the paired t-test (AUC = 0.80). Cancer Informatics 2007:3 217
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genes. Ignoring these inﬂ  uences will simply intro-
duce noise in feature selection resulting in low 
accuracy of the classiﬁ  er. 
A good classiﬁ  cation signature should be a 
minimal subset of genes that is not only differen-
tially expressed but also contains most relevant 
genes without redundancy (Peng et al. 2006; 
Baker and Kramer, 2006). A comparative analysis 
on data across several studies has found that clas-
siﬁ  cation rules for 5 genes can achieve compa-
rable performance as that for 20 or 50 genes 
(Baker and Kramer, 2006). In our analysis, the 
high performance is achieved by basing our clas-
siﬁ  er coincidently on 5 informative genes. It is 
interesting that all 5 genes overlap with the 
32-gene signature identiﬁ  ed by PAM (Thomassen 
et al. 2006a) and 2 of the 5 genes overlap with the 
70-gene signature from van’t Veer et al. (2002) 
in their studies on breast cancer metastases. 
Further information on the 5 selected genes is 
provided in Table 1. 
Finally, it is necessary to point out that the 
paired experiment design in studying tumor metas-
tasis using two-channel cDNA microarrays can be 
further advantaged by the reduced experimental 
cost when directly labeling, for example, metas-
tasis mRNA with cy5 and non-metastasis mRNA 
with cy3 in each matched pair. Since our method 
works with the pair-wised difference in the log 
expression values, the feature selection algorithm 
is valid for both one- and two- channel microarray 
platforms. Overall, given the popularity of the pair 
matched design in cancer studies, we hope that our 
new method for feature selection can be of use in 
identifying efﬁ  cient and informative gene expres-
sion signatures for predicting tumor metastases in 
clinical cancer research. 
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